Anemia Clinical Trial
Official title:
The Effects of One Month Consumption of Standardized Aronia Melanocarpa Extract on Anemia in Patients on Hemodialysis: Focus on Oxidative Stress and Inflammation
In this study are included patients on hemodialysis with anemia (levels of Hemoglobin<110). After baseline measurements tha patients take Standardized Aronia melanocarpa extract for one mont and then all measurements were repeated.
1. Patients The study included 30 patients with chronic kidney failure on dialysis
treatment at the Center for Nephrology and Dialysis of the Clinical Center Kragujevac.
Inclusion criteria were: regular dialysis treatment for more than 3 months, 3 times a
week and hemoglobin values lower than 110g / L. Exclusion criteria were: hemoglobin
values lower than 80g/L, the use of antioxidant and immunosuppressive therapy,
uncontrolled malignancies, proven active bleeding and presence of systemic inflammation
or active infection.
2. Ethical approval The research was conducted with respect to the Helsinki Declaration on
Medical Research, the approval of the Ethics Committee of the Clinical Center Kragujevac
No 01-14-3039. All subjects provided written informed consent before study enrollment.
3. Used plant extract Standardized Aronia extract (SAE) is official product of
pharmaceutical company Pharmanova (Belgrade, Serbia); nevertheless, procedure of
extraction was done by EU-Chem company (Belgrade, Serbia). This product contains
400mg/30ml of polyphenols, while the recommended daily dosage is 30ml.
4. Blood sampling Patients included in the study consumed standardized Aronia melanocarpa
extract (30ml/day) for 30 days. On the day 0, before SAE consumption, blood samples from
all patients were collected for hematologic analyzes, inflammation parameters, oxidative
stress parameters and antioxidant protection before the dialysis procedure. All
mentioned parameters were determined again after consuming the product, ie. on the 30th
day of the study.
5. Analytic Procedures Venous blood samples (2 x 4.5ml) were taken before the start of
supplementation (zero day) and at the end of supplementation (30th day). Vacuum tubes
with sodium citrate were used for blood sampling. The first sample was used for routine
hematologic analyzes, the second sample was used for plasma and erythrocyte lysate
extraction in order to determinate redox and inflammatory status.
6. Evaluation of Systemic Redox State Plasma samples were used for determination of the
levels of the following pro-oxidants: superoxide anion radical (O2−), hydrogen peroxide
(H2O2), nitrites (NO2−) and index of lipid peroxidation measured as thiobarbituric acid
reactive substances (TBARS), while the parameters of antioxidative defence system, such
as activities of superoxide dismutase (SOD) and catalase (CAT) and level of reduced
glutathione (GSH) were determined in erythrocytes lysates samples.
A) Index of lipid peroxidation (TBARS) determination The degree of lipid peroxidation in
the plasma samples was estimated by measuring TBARS, using 1% thiobarbituric acid in
0.05 NaOH, which was incubated with the sample at 100°C for 15 min and measured at 530
nm. TBA extract was obtained by combining 0.8 ml sample and 0.4 ml trichloro acetic acid
(TCA); afterwards, the samples were put on ice for 10 min and centrifuged for 15 min at
6000 rpm. (1).
b) Nitrite determination (NO2-)
Nitric oxide (NO) decomposes rapidly to form stable nitrite/nitrate products. The NO2−
level was measured and used as an index of NO production, using Griess's reagent. For
NO2 − determination in plasma 0.1 ml 3 N PCA (perchloride acid), 0.4 ml 20 mM
ethylenediaminetetraacetic acid (EDTA) and 0.2 ml plasma were put on ice for 15 min,
then centrifuged for 15 min at 6000 rpm. After pouring off the supernatant, 220 μl K2CO3
was added. Nitrites were measured at 550 nm. (2)
1. Superoxide anion radical determination (O2-)
Superoxide anion radical concentrations in plasma samples were measured using the
NTB (Nitro Blue Tetrazolium) reagent in TRIS buffer (assay mixture). The
measurement was performed at a wavelength of 530 nm. (3).
2. Hydrogen peroxide determination (H2O2)
The measurement of H2O2 was based on the oxidation of phenol red by H2O2 in a
reaction catalyzed by horseradish peroxidase. Two hundred microlitres of perfusate
or plasma was precipitated using 800 mL of freshly prepared phenol red solution; 10
μL of (1:20) horseradish peroxidase (made immediately before use) was subsequently
added. The level of H2O2 was measured at 610 nm (4).
3. Determination of reduced glutathione (GSH)
The level of reduced glutathione (GSH) was determined based on GSH oxidation via
5,5-dithiobis-6,2-nitrobenzoic acid. GSH extract was obtained by combining 0.1 ml
0.1% EDTA, 400 μl hemolysate, and 750 μl precipitation solution (containing 1.67 g
metaphosphoric acid, 0.2 g EDTA, 30 g NaCl, and filled with distilled water until
100 ml; the solution is stable for 3 weeks at +4C°). The level of GSH was measured
at 420 nm (5).
4. Determination of antioxidant enzymes (SOD, CAT)
Isolated RBCs were washed three times with three volumes of ice-cold 0.9 mmol/l NaCl,
and hemolysates containing about 50 g Hb/l were used for the determination of CAT
activity. CAT buffer, prepared hemolysate sample, and 10 mM H2O2 were used for CAT
determination. Detection was performed at 360 nm. SOD activity was determined by the
epinephrine method. Hemolysate was mixed with carbonate buffer, and then epinephrine was
added. Detection was performed at 470 nm (6-10).
7. Evaluation of the inflammatory status In order to evaluate the inflammatory status of
patients, following parameters were measured at both points of interest (0 and 30th
day): serum C-reactive protein concentration - CRP and tumor necrosis factor
concentration - TNF-α.
The serum C- reactive protein (CRP) concentration was determined by the turbidimetric
method on the Olympus AU680. The normal serum CRP concentration is ≤ 5 mg/L.
Microinflammation is defined as the concentration of CRP in the serum of 5 mg/L.
Plasma TNF-α concentrations were determined by enzyme linked immunoadsorbent assay
(ELISA) using commercially available high sensitivity indirect sandwich enzyme-linked
immunosorbent assay (Sigma Aldrich).
8. Evaluation of the hematological parameters
At both points of interest, the values of the following haematological parameters in all
patients were analyzed:
Erythrocytes (Er), hemoglobin (Hb), hematocrit (Hct), erythrocyte index- mean
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin
concentration (MCHC), serum lactate dehydrogenase concentration (LDH), serum haptoglobin
concentration and iron status: serum iron concentration, ferritin; total iron binding
capacity (TIBC), unsaturated iron binding capacity (UIBC), transferrin saturation
(TSAT), haptoglobin.
9. Statistical Analysis IBM SPSS Statistics 20.0 Desktop for Windows was used for
statistical analysis. Shapiro-Wilk test was used to check the distribution of data.
Statistical comparisons were performed using the one-way analysis of variance (ANOVA)
tests with a Tukey's post hoc test for multiple comparisons, in the case of normal
distribution of data between groups, while Kruskal-Wallis was used for comparison
between groups where the distribution of data was different than normal. Values of p <
0.05 were considered to be statistically significant.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A |